Phase 3Terminated
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)
A Randomized Phase III Trial of Trastuzumab + ALpelisib +/- Fulvestrant Versus Trastuzumab + Chemotherapy in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer. "ALPHABET Study".
- Sponsor
- Spanish Breast Cancer Research Group (Academic or other)
- Enrolment
- 27 enrolled
- Conditions
- Advanced Breast Cancer
- Interventions
- Trastuzumab; Alpelisib; Fulvestrant; Vinorelbine; Capecitabine; Eribulin
- Ages
- adults, older adults
- Registry
- NCT05063786, EUCTR2020-005639-65
Full record on ClinicalTrials.gov
From the registry
Randomized phase III trial of trastuzumab + Alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ Advanced Breast cancer.
Primary outcomes
- Progression Free Survival (PFS)
History
Last registry update
Primary completion
Registered
Started